S.R.Y Medical Services LTD is an Israeli company that manufactures and develops radiopharmaceuticals for diagnosis, treatment and medical research.
S.R.Y Medical Services LTD operates the cyclotron unit at Hadassah Medical Organization (HMO), Jerusalem, Israel, and produces radio-pharmaceuticals in state-of-the-art manufacturing facilities. The company holds a GMP (Good Manufacturing Practice) certificate for one of the production lines, and a GPP (Good Preparation Practice) certificate for the radio-pharmacy, under the supervision of the Israeli Ministry of Health. S.R.Y is a leading company in the national radiopharmaceutical market, providing service and delivers radio-pharmaceuticals on a daily basis to most of the hospitals throughout Israel.
The Hadassah Cyclotron Unit was established in 1996 by Prof. Eyal Mishani, the company’s CEO, and was the first in Israel to operate a particle accelerator for medical purposes. The establishment of the Cyclotron Unit has promoted medicine in Israel by making PET imaging an integral part of the diagnosis process of cancer patients. In 2010 the unit upgraded its production capacity by installing another cyclotron, thus becoming the only complex in Israel that holds two cyclotrons. In 2016, S.R.Y Medical Services LTD was established as a subsidiary of Hadassah Medical Organization with a long-standing and experienced staff in the field of radio-pharmaceutical production.
S.R.Y operates a new and advanced manufacturing site, at an international level, and since its inception has quickly established its position as a leading radio-pharmaceutical company in Israel.
S.R.Y is equipped with the most advanced technology and manufactures according to uncompromising standards, to meet the most stringent global threshold and regulations. The company owns two 18 MeV IBA cyclotrons, an array of 68Ge-68Ga generators, a dozen automatic modules and two production clean rooms, containing hot cells and three ‘Grade A’ isolators for production of a wide range of radiopharmaceuticals. The quality control tests are carried out in advanced quality control laboratories with state-of-the-art analytical equipment and cutting-edge apparatuses.
S.R.Y’s CEO, Professor Eyal Mishani, is among the world’s pioneers in the field of radiochemistry and PET radiopharmaceuticals, with 30 years of experience. Prof. Mishani serves as a global expert in quality assurance in nuclear medicine on behalf of the International Atomic Energy Agency (IAEA). S.R.Y’s diverse and skilled staff includes over 30 professional personnel: researchers and scientists with PhD degrees, as well as chemists, physicists, biologists, biotechnologists, pharmacists and engineers from various fields, who manage and operate the company’s production, quality control, quality assurance, development, maintenance, service and administration departments efficiently and faithfully.
S.R.Y operates at the forefront of science and technology and is engaged in research and development of new radiopharmaceuticals. By doing so, the company aims to promote the field of PET molecular imaging and patient care, both at the national and the international levels.
[18F]-2-fluorodeoxyglucose is a glucose analogue, labeled with 18F. It is the most prevalent PET pharmaceutical in oncology, commonly used for diagnosis, follow-up and early assessment of treatment efficacy.
Similar to [68Ga]PSMA-11, this ligand targets the prostate-specific membrane antigen (PSMA), which is expressed on prostate cancer (PC) cells. However, owing to its minimal urinary excretion, it offers higher sensitivity in detection of localized advanced PC.
([18F]flutemetamol) is used for imaging of -amyloid plaque density in the brain of adult patients with cognitive impairment, as part of an early evaluation of Alzheimer’s disease.
A levodopa analogue, used for visualization of dopaminergic nerve terminals in the striatum and assessment of Parkinson’s disease.
[18F]fluorodihydrotestosterone is used for molecular imaging of the androgen receptor. Its clinical utility for imaging glioblastoma multiform (GBM) is under investigation.
A PET ligand targeting the prostate-specific membrane antigen (PSMA), which is expressed on prostate cancer (PC) cells. Used for clinical decision making both in initial staging of high-risk PC patients and in biochemical recurrence.
This 68Ga-labeled somatostatin analogue binds somatostatin-receptor subtypes 2 (SSTR2) with high affinity. It is used for initial diagnosis and imaging of neuroendocrine tumors (NETs) and for patient selection prior to peptide-receptor radiotherapy (PRRT) with [177Lu]DOTA-TATE.
A therapeutic radiopharmaceutical for PRRT of advanced/ non-resectable NETs in patients whose tumors express SSTR2, as indicated by [68Ga]DOTA-TATE scan.